Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein |
Zhou, Yong-Fei
(National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University)
Nie, Jiao-Jiao (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) Shi, Chao (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) Ning, Ke (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) Cao, Yu-Feng (Immune-Path Biotechnology (Suzhou) Co., Ltd.) Xie, Yanbo (Jilin Provincial Key Laboratory of Agricultural Biotechnology, Jilin Academy of Agricultural Sciences) Xiang, Hongyu (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) Xie, Qiuhong (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) |
1 | de Wit E, van Doremalen N, Falzarano D, Munster VJ. 2016. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14: 523-534. DOI |
2 | Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273. DOI |
3 | Yang Y, Islam MS, Wang J, Li Y, Chen X. 2020. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int. J. Biol. Sci. 16: 1708-1717. DOI |
4 | Hu B, Guo H, Zhou P, Shi ZL. 2021. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19: 141-154. DOI |
5 | Izda V, Jeffries MA, Sawalha AH. 2021. COVID-19: a review of therapeutic strategies and vaccine candidates. Clin. Immunol. 222: 108634. DOI |
6 | Mulligan MJ, Lyke KE, Kitchin N, Absalon J. 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586: 589-593. DOI |
7 | Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 397: 99-111. DOI |
8 | Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 21: 181-192. DOI |
9 | Wei M, Zhang X, Yu H, Tang ZM, Wang K, Li Z, et al. 2014. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. Vaccine 32: 2859-2865. DOI |
10 | Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. 2015. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10: 845-858. DOI |
11 | Castells MC, Phillips EJ. 2021. Maintaining safety with SARS-CoV-2 vaccines. New Engl. J. Med. 384: 643-649. DOI |
12 | He P, Zou Y, and Hu Z. 2015. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum. Vaccin. Immunother. 11: 477-488. DOI |
13 | Iserson KV. 2021. SARS-CoV-2 (COVID-19) Vaccine development and production: an ethical way forward. Camb. Q Healthc Ethics 30: 59-68. DOI |
14 | Yadav T, Srivastava N, Mishra G, Dhama K. 2020. Recombinant vaccines for COVID-19. Hum. Vaccin. Immunother. 16: 2905-2912. DOI |
15 | Rahimi A, Mirzazadeh A, Tavakolpour S. 2021. Genetics and genomics of SARS-CoV-2: a review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics 113: 1221-1232. DOI |
16 | Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. 2020. The epidemiology and clinical information about COVID-19. Eur. J. Clin. Microbiol. Infect. Dis. 39: 1011-1019. DOI |
17 | Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. 2020. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front. Cell. Infect. Microbiol. 10: 587269. DOI |
18 | Soleimanpour S and Yaghoubi A. 2021. COVID-19 vaccine: where are we now and where should we go? Expert Rev. Vaccines 20: 23-44. DOI |
19 | Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. 2020. Safety and efficacy of the BNT162b2 mRNA Covid19 vaccine. New Engl. J. Med. 383: 2603-2615. DOI |
20 | Mahase E. 2020. Covid-19: moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy. BMJ. 371: m4709. DOI |
21 | Mahase E. 2021. How the Oxford-AstraZeneca covid-19 vaccine was made. BMJ. 372: n86. DOI |
22 | Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. 2010. Virus-like particles in vaccine development. Expert Rev. Vaccines 9: 1149-1176. DOI |
23 | Li L, Guo P, Zhang X, Yu Z, Zhang W, Sun H. 2021. SARS-CoV-2 vaccine candidates in rapid development. Hum. Vaccin. Immunother. 17: 644-653. DOI |
24 | Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, et al. 2013. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499: 102-106. DOI |
25 | Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. 2020. Establishment and validation of a pseudovirus neutralization assay for SARSCoV-2. Emerg. Microbes Infect. 9: 680-686. DOI |
26 | Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y, et al. 2020. Nanoparticle vaccines based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53: 1315-30.e9. DOI |
27 | Knoll MD and Wonodi C. 2021. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet (London, England) 397: 72-74. DOI |
28 | Hernandez AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. 2021. Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol. Rep. 8: 871-879. DOI |
29 | Ghorbani A, Zare F, Sazegari S, Afsharifar A, Eskandari MH, and Pormohammad A. 2020. Development of a novel platform of viruslike particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach. New Microbes New Infect. 38: 100786. DOI |
30 | Kim C, Kim JD, Seo SU. 2022. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. J. Microbiol. 60: 335-346. DOI |